Summit Therapeutics Inc [SMMT] stock prices are down -0.17% to $18.12 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SMMT shares have gain 5.17% over the last week, with a monthly amount glided 11.92%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Summit Therapeutics Inc [NASDAQ: SMMT] stock has seen the most recent analyst activity on December 17, 2025, when Barclays upgraded its rating to a Equal Weight but kept the price target unchanged to $18 for it. On September 17, 2025, Barclays initiated with a Underweight rating and assigned a price target of $13 on the stock. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $40 on September 04, 2025. Piper Sandler initiated its recommendation with a Neutral and recommended $21 as its price target on August 19, 2025. UBS started tracking with a Buy rating for this stock on July 01, 2025, and assigned it a price target of $30. In a note dated June 11, 2025, Leerink Partners initiated an Underperform rating and provided a target price of $12 on this stock.
The stock price of Summit Therapeutics Inc [SMMT] has been fluctuating between $15.55 and $36.91 over the past year. Currently, Wall Street analysts expect the stock to reach $24.67 within the next 12 months. Summit Therapeutics Inc [NASDAQ: SMMT] shares were valued at $18.12 at the most recent close of the market. An investor can expect a potential return of 36.15% based on the average SMMT price forecast.
Analyzing the SMMT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -3.52, Equity is -3.11 and Total Capital is -4.75. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.79 points at the first support level, and at 17.47 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.35, and for the 2nd resistance point, it is at 18.59.
Ratios To Look Out For
It’s worth pointing out that Summit Therapeutics Inc [NASDAQ:SMMT]’s Current Ratio is 3.80. As well, the Quick Ratio is 3.80, while the Cash Ratio is 3.68.
Transactions by insiders
Recent insider trading involved Xia Yu, Director, that happened on Oct 21 ’25 when 0.53 million shares were purchased. Co-Chief Executive Officer, DUGGAN ROBERT W completed a deal on Oct 21 ’25 to buy 26680.0 shares. Meanwhile, Co-Chief Executive Officer Zanganeh Mahkam bought 26680.0 shares on Oct 21 ’25.
